Table 1.
Characteristics of the study participants
| Variable | TMA patients (excluding STEC-HUS) (n = 44)a | STEC-HUS (n = 30)a | Controls (n = 112) |
|---|---|---|---|
| Age, years | 38 (22–55) | 4 (1–69) | 34 (27–41) |
| Female/male ratio | 28/16 | 22/8 | 67/45 |
| Subgroup | |||
| ADAMTS13-deficient TTP | 17 | ||
| aHUS | 9 | ||
| Secondary TMA | 18 | ||
| Kidney injury (none/acute only/ acute on chronic/chronic only), n | 20/20/3/1 | 0/30/0/0 | None |
| Creatinine, µmol/l | 85 (63.75–136.75) | 286.5 (38–862) | 69 (62–83) |
| Haemoglobin, g/l | 85 (70.5–97.5) | 91 (61–136) | 138 (128–149) |
| Platelets, g/l | 41 (23–73.5) | 43 (13–436) | 276 (25–317) |
| Lactate dehydrogenase activity, U/l | 1,791 (672–3,036) | 2,021 (54–6,348) | N/A |
Data represent medians (IQR) or numbers of subjects unless otherwise stated. N/A = Not available.
a
With the available sample for NET degradation analysis taken before the initiation of plasma therapy.